Illumina, Inc. · NASDAQ:ILMN
Illumina — Solexa — Merger or Acquisition (January 2007)
36 slides from Illumina's merger presentation, Jan 12, 2007
Slide 1: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Illumina, Inc. ("Illumina") and Solexa, Inc. ("Solexa") caution readers that any forward-looking information is not a guarantee of future performance and actual results could differ
Slide 2: Highlights of Breakout Year in 2006
Highlights of Breakout Year in 2006 Over plan financial performance Growth in Whole Genome Genotyping Business Progress in expression business Capacity build out Diagnostic partnerships Solexa merger
Slide 3: Non-GAAP Q3 Financial Performance
Revenue $53,472 $ 19,516 $ 73,501 COGS 15,939 6,599 23,181 Gross Margin 37,533 12,917 50,320 % 70.2% 66.2% 68.5% R&D 6,790 7,062 27,725 SG&A 11,734 7,276 27,972 Net Income* 19,917 (1,309) (20,874)** EPS* $0.39 $(0.03) $(0.52)** Non-GAAP Q3 Financial Performance Note: All Numbers in Thousands. (*) Ex
Slide 4: ASP for Infinium Product Family
ASP for Infinium Product Family $ Per Chip
Slide 5: Rapid Growth in Installed Base
Rapid Growth in Installed Base
Slide 6: 2006 New Products in Infinium Family
2006 New Products in InfiniumTM Family
Slide 7: Recent Deal Summary
Recent Deal Summary Customer Disease # Samples Product Bovine Consortium Breeding 10,000 iSelect Std. product deCODE Various 100,000 HumanHap300 CHOP Children's diseases 30,000 HumanHap550 Duke University Autism 1,800 HumanHap550 Top 5 Pharma Not disclosed 3,200 initially HumanHap650Y Amgen Woman's
Slide 8: Comprehensive Suite of Gene Expression Products
Comprehensive Suite of Gene Expression Products Screening Toxicology Dx panels Cell cultures Fresh tissue Paraffin Embedded Tissue Biomarkers discovery
Slide 9: Confidential
Confidential
Slide 10: Diagnostic Partnerships
Diagnostic Partnerships deCODE ig genetics GENIZON BioSciences Realietrix Gp” Children’s Hospital of Eastern Ontario ‘Centre hospital pour enfants de Vest de FOntario illumina
Slide 11: Creating A Powerful Life Science Franchise
Creating A Powerful Life Science Franchise Leading provider of genotyping & gene expression solutions Addressable market: $1.25 billion 2006 World-class commercial infrastructure 21 consecutive quarters of revenue growth Industry leading margins (30% net income in Q3 '06) "Best-of-Breed" next genera
Slide 12: Solexa's Technology: The 1G Genome Analyzer
100x lower cost than today's standard Proprietary sequencing by synthesis chemistry Early access program successfully completed Comprehensive IP portfolio Recent validation - Human X Chromosome Solexa's Technology The 1G Genome Analyzer
Slide 13: Solexa Technical Approach
Solexa Technical Approach DNA Clusters About 500 DNA copies per cluster Each about 1 micron in diameter Amplify DNA Sequencing Chemistry Extend by one base each step 4 fluorescent colors correspond to the 4 bases Computer-controlled Imaging tens of millions of clusters in parallel Solexa digital ima
Slide 14: Key Technology Advantages
Key Technology Advantages Solexa Conventional Capillary Systems Basic operating scale Microscopic Macroscopic Sequences in parallel Up to 40 million 96 Instrument time per human genome < 1/2 machine year 50 machine years Consumables per human genome 60 chips Stack of 384-well plates 9x higher than E
Slide 15: Integration of Sequencing and Genotyping Applications
Whole Genome Resequencing SNP discovery Rate mutation discovery Whole Genome Genotyping Disease associations 100,000's markers Focused Genotyping Fine mapping Validation 1,000's SNPs SNP Screening Validation 100's SNPs Biomarker discovery Diagnostic Genotyping Low-plex panels PGx Diagnostic Sequenci
Slide 16: Recent Developments and Progress
Recent Developments and Progress Completed Early Access Program 13 systems installed 10 customer sites 5 countries Began invoicing Received initial payments Achieved 1G performance 1 Billion bases of DNA sequence from a single flow cell (after filtering) Full performance level for initial product De
Slide 17: Financial Highlights of Transaction
Financial Highlights of Transaction Estimated to be 20 to 35% dilutive in 2007, excluding merger related charges Modestly accretive transaction in 2008 and significantly accretive thereafter Anticipated Synergies Integrated sales force accelerates revenue opportunity Reallocation of Illumina R&D res
Slide 18: Launch of DNA Methylation Application
Launch of DNA Methylation Application Dramatic Increase in Speed and Scope of DNA Methylation Research
Slide 19: DNA Methylation
DNA Methylation DNA methylation - a type of chemical modification of DNA that can be inherited without changing the DNA sequence Involves the addition of a methyl group to DNA Widespread and plays a critical role in the regulation of gene expression. Abnormalities in gene methylation are linked to:
Slide 20: Methylation Product Offering
Methylation Product Offering GoldenGate Assay for Methylation: First standard product available now - GoldenGate Methylation Cancer Panel I ~800 cancer genes; 1-3 sites/gene Custom methylation version to ship soon - allows customer to select genes of interest
Slide 21: Methylation Profiles of Cancer Cell Lines
Methylation Profiles of Cancer Cell Lines All cancer samples correctly separated from normal Highly specific methylation signatures were obtained for each cancer type.
Slide 22: Biomarkers for Cancer Cell Lines
Biomarkers for Cancer Cell Lines Only 10 loci separate all normal samples from all cancer cell lines! normal cancer
Slide 23: First System Based on VeraCode Technology
First System Based on VeraCode Technology Digital Microbead Technology CyVera Company Purchased April 2005
Slide 24: Technology / Platform Synergy
Technology / Platform Synergy Discovery Research Focused Research Molecular Diagnostics WG genotyping WG expression Biomarker discovery Future WG applications Custom genotyping Focused expression DASL Biomarker discovery Low/mid density GT/GEX Protein applications Biomarker screening Biomarker panel
Slide 25: Digital Code Generation
Digital Code Generation CODE IMAGE 1 0 1 1 0 1 0 1 0 0 0 0 1 0 1 BINARY CODE DECIMAL CODE = 41133 CODE GENERATED BY CREATING EMBEDDED HOLOGRAPHIC DIFFRACTIVE ELEMENTS Glass Surface of Beads Ideal for Bioassays High Density Codes Easily Imprinted (24 bit) Virtually Unlimited Multiplexing CONVENTIONAL
Slide 26: Beads Align in Groove Plate
Beads Align in Groove Plate GROOVE PLATE CROSS-SECTION BEADS FALL INTO GROOVE PLATE CAPILLARY FORCE ATTRACTS BEADS INTO GROOVES BEADS ALIGN TIGHTLY FOR OPTIMAL SCANNING EFFICIENCY
Slide 27: Code Detection
Code Detection BEAD "READING" BEAM CCD LINE ARRAY
Slide 28: Distribution, Chemistry and Content Synergy
Distribution, Chemistry and Content Synergy Shared Chemistry Shared Content Shared Distribution Industry leading genotyping platform Flexible, scalable array technology Targets research market Launch next few months High sample throughput, low to mid multiplex Targets research and diagnostic market
Slide 29: The Near-Term Future of Infinium Product Line
The Near-Term Future of Infinium Product Line
Slide 30: What Factors are Important in the Market?
What Factors are Important in the Market? Genomic Coverage Quality of data delivered Robustness of assay and ease of use Copy Number Polymorphism content Backward compatibility Family of products allowing optimized projects
Slide 31: Illumina's Human 1M BeadChip
Illumina's Human 1M BeadChip Unsurpassed power and gene coverage for whole genome association (WGA) and copy number variant (CNV) analyses Based on HumanHap550 content with additional 450K features (SNPs & non-SNPs) A single chip solution providing industry leading genomic coverage, data quality and
Slide 32: Human 1M BeadChip Content
Human 1M BeadChip Content HumanHap550 555,000 High genomic coverage SNPs in Genes 250,000 High density of SNPs in coding regions of the genome SNPs and Probes in both reported and novel Copy Number Variant (CNV) Regions 110,000 High density of SNPs and probes in CNV regions, including "nonSNPable" r
Slide 33: Human 1M BeadChip Content
eT — Human 1M BeadChip Content ‘SNPs and Probes (in both reported and novel CNV Regions) SNPs in Genes Additional YRI Tag SNPs with lower density of coverage in HapMap Additional CEU and CHB+JPT Tag SNPs Even Spacin \ 7 nome! Human-t MHC. ‘SNPs Ps incoding Walken y (1% MAF) SNPs insertions 7 Deletio
Slide 34: Upgradeable and Compatible Products
Upgradeable and Compatible Products
Slide 35: Summary
Summary Multi-billion dollar opportunity in research and molecular diagnostics markets BeadArray technology is fundamentally flexible, low-cost and scalable. Solexa technology best-of-breed. Our portfolio of products is growing quickly enabled by a well developed infrastructure and innovative assay
Slide 36: Slide 36